Non-Small Cell Lung Cancer (NSCLC)Symptoms, Doctors, Treatments, Advances & More
Non-Small Cell Lung Cancer (NSCLC) Overview
Learn About Non-Small Cell Lung Cancer (NSCLC)
View Main Condition: Lung Cancer
Common conditions include: EGFR Positive Lung Cancer, Large-Cell Lung Carcinoma, Lung Adenocarcinoma, Squamous Cell Lung Carcinoma
Duke Cancer Center
Thomas Stinchcombe is an Oncologist and a Hematologist Oncology provider practicing medicine in Durham, North Carolina. Dr. Stinchcombe is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), EGFR Positive Lung Cancer, and Gamma Knife Radiosurgery. Dr. Stinchcombe is board certified in American Board Of Internal Med, Medical Oncology. Dr. Stinchcombe is currently accepting new patients.
Young Chae is a Hematologist and an Oncologist practicing medicine in Chicago, Illinois. Dr. Chae is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 28 other conditions, according to our data. His clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, Small Cell Lung Cancer (SCLC), and Tissue Biopsy. Dr. Chae is board certified in American Board Of Internal Medicine - Medical Oncology (Certified). Dr. Chae is currently accepting new patients.
NYU Langone Hospitals
Joshua Sabari is an Oncologist practicing medicine in New York, New York. Dr. Sabari is rated as an Elite provider by MediFind in the treatment of Non-Small Cell Lung Cancer (NSCLC). He is also highly rated in 13 other conditions, according to our data. His clinical expertise encompasses Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, EGFR Positive Lung Cancer, Tissue Biopsy, and Thrombectomy.
Summary: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Summary: The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
